Tao Osgood
Amgen (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer-related Molecular Pathways, CAR-T cell therapy research, Immune Cell Function and Interaction
Most-Cited Works
- → The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity(2019)2,187 cited
- → AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies(2018)409 cited
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction(2012)167 cited
- → The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents(2015)145 cited
- → Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors(2013)84 cited
- → Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction(2014)83 cited
- → MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways(2014)55 cited
- → Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo(2008)55 cited
- → Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres(2014)54 cited